AstraZeneca will pay insitro $40 million upfront to apply AI to target discovery in MASH and cardiomyopathies, with no candidates named yet.
|Articles|November 9, 2021
- Pharmaceutical Executive-11-01-2021
- Volume 41
- Issue 11
Pharmaceutical Executive, November 2021 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive November 2021 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 5 years ago
In It For the Long-Haul: Planning for the Future of COVID-19almost 5 years ago
Turning the Corner: A New Era of Pharma Sales Comes Into Viewalmost 5 years ago
An Industry Under Attack: Pharma Revisits Cybersecurity During COVID-19almost 5 years ago
The New COVID Workforce: Keeping Pharma Strong Through Adversityalmost 5 years ago
Crafting Curesalmost 5 years ago
Could 2022 Prove to Be Better Year for Biotech Companies?almost 5 years ago
COVID and the Data Talent Turnaboutalmost 5 years ago
Talent Pipelines Can Position Companies for Greater Hiring Successalmost 5 years ago
EU MEPs Arrive At Crossroads in Cancer Strategyalmost 5 years ago
Pharm Exec at 40 (2015-2018)Advertisement
Related to this article
AI does not end uncertainty in pharma strategy. Its value depends on how well leaders blend it with experience and evidence while keeping judgment human.
Fox Rothschild's Marc Wagner on why domestic manufacturing reduces drug shortage risk — and why FDA inspection efficiency is as important as supply chain resilience.
MERGE's Pat McGloin on why pharma AI fails when strategy follows technology — and why the brilliant basics still have to come first.
FDA is launching the Rare Disease Framework Initiative, aiming to tailor drug development and review requirements to the realities of small patient populations.
Gilead and Vir Biotechnology strike a $1.87 billion T-cell engager collaboration, and Fox Rothschild’s Marc Wagner examines what slows manufacturers’ response to rising drug demand and how compounding pharmacies help fill the resulting gaps.
Gilead and Vir Biotechnology Enter a $1.87 billion collaboration to discover three PRO-XTEN dual-masked T-cell engagers aimed at solid tumors.
Fox Rothschild's Marc Wagner on how 503A pharmacies and 503B outsourcing facilities fill drug supply gaps — from COVID injectables to GLP-1s.
Advertisement
Advertisement
Trending on PharmExec
1
The Impact That the Renewed Focus on Domestic Manufacturing Might Have on the Supply Chain
2
FDA Launches Rare Disease Framework Initiative
3
Pharmaceutical Executive Daily: Gilead Enters $1.87 Billion Collaboration and License Agreement with Vir Biotechnology
4
AstraZeneca Taps insitro AI for MASH in Deal Worth Up to $1.5 Billion
5